Trant, Amelia A.
Szekely, Borbala
Mougalian, Sarah S.
DiGiovanna, Michael P.
Sanft, Tara
Hofstatter, Erin
Silber, Andrea
Adelson, Kerin B.
Chagpar, Anees
Killelea, Brigid
Horowitz, Nina
Lannin, Donald
Park, Tristen
Corso, Michelle
Abraham, Gineesha
Pollard-Murphy, Karen
Sturrock, Tracy
Knill-Selby, Elspeth
Western, Ashley
Servodidio, Camille
Tasoulis, Marios Konstantinos
Healy, Barbara
Hatzis, Christos
Pusztai, Lajos http://orcid.org/0000-0001-9632-6686
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-16-130)
Article History
Received: 17 December 2018
Accepted: 10 April 2019
First Online: 25 April 2019
Compliance with ethical standards
:
: Dr. Mougalian is a consultant for Eisai Pharmaceuticals and Puma Biotechnology. Dr. DiGiovanna receives remuneration from DAKO and NeoMarkers and consultants for Merck. Dr. Silber receives remuneration from AstraZeneca. Dr. Adelson is a consultant for Celgene, Roche, and Heron Therapeutics. Dr. Killelea is a consultant for Genentech. All other authors declare that they have no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Yale Institutional Review Board and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.